High-Throughput Dried Blood Spot (HT-DBS) Technologies in SARS COV-2 Serology and Vaccinology
Document text
Principal Investigator: Nicholas J. Mantis Organization: WADSWORTH CENTER Fiscal Year: 2020 Award: $1,153,230 Funding agency: National Cancer Institute Project Summary As the COVID-19 pandemic continues to spread across the United States it is imperative that we implement technologies to screen large swaths of the population for the presence of antibodies to SARS-CoV-2. Serological surveillance not only affords a measure of virus exposure within a community at large but also provides information necessary to predict outbreak dynamics. Furthermore, as our understanding of how humoral factors contribute to controlling (and possibly exacerbating) COVID-19, it will be essential to have methods in place to measure the “quantity” and “quality” of antibodies associated with both natural SARS-CoV- 2 exposure and candidate SARS-CoV-2 vaccines. This U01 proposal seeks to advance the use of dried blood spots (DBS) in conjunction with a Luminex-based microsphere immunoassay (MIA) to enable high-throughput (HT) population-wide serological surveillance for SARS-CoV-2. Specifically, the proposal will expand the HT- DBS assay to capture the breadth and complexity of SARS-CoV-2 antibody responses following natural infection, and develop a high-throughput competitive immunoassay (CIA) as a surrogate measure of SARS- CoV-2 neutralizing antibody titers in DBS. The proposed platform technologies to be developed at the Wadsworth Center will contribute directly to NCI’s mission to “… develop, validate, improve and implement serological testing and associated technologies…” to address the COVID-19 pandemic. Terms: <19S Gamma Globulin><2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><Address><Antibodies><Antibody Response><Antibody titer measurement><Antigens><Assay><Bioassay><Biologic Assays><Biological Assay><Blood><Blood Plasma><Blood Reticuloendothelial System><Blood Serum><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Clinical><Communities><Disease Outbreaks><Employee><Food Services><General Population><General Public><Goals><HCV/HIV><HIV and HCV><HIV and hepatitis C><HIV-HCV><HIV/HCV><HIV/Hepatitis C><Health><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><Hordeolum><Human><IgA><IgG><IgM><Immunity><Immunoassay><Immunoglobulin A><Immunoglobulin G><Immunoglobulin M><Individual><Infection><Laboratories><Liquid substance><Measures><Methodology><Methods><Microbeads><Microspheres><Mission><Modeling><Modern Man><NCI Organization><NIAID><National Cancer Institute><National Institute of Allergy and Infectious Disease><New York><Outbreaks><Plasma><Plasma Serum><Population><Principal Investigator><Proteins><Reticuloendothelial System, Serum, Plasma><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Saliva><Sampling><Schools><Science><Sensitivity and Specificity><Serologic><Serologic tests><Serological><Serological Tests><Seroprevalences><Serum><Severe acute respiratory syndrome coronavirus 2><Spottings><Stye><Technology><Testing><Time><United States><Vaccines><Virus><Work><Wuhan coronavirus><antibody titering><base><co-infection><cohort><coinfection><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><first responder><fluid><health care personnel><health care worker><health provider><health workforce><healthcare personnel><immunogen><immunological status><improved><liquid><medical personnel><member><minimally invasive><neutralizing antibody><neutralizing mAb><neutralizing monoclonal antibodies><non-human primate><nonhuman primate><pre-clinical><preclinical><sample collection><serology><specimen collection><treatment provider><vaccination study><vaccination trial><vaccine candidate><vaccine study><vaccine trial><vaccinology>